Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine.

Journal of Lipid Research
Jean-Marie BrusqMarc Issandou

Abstract

The alkaloid drug berberine (BBR) was recently described to decrease plasma cholesterol and triglycerides (TGs) in hypercholesterolemic patients by increasing expression of the hepatic low density lipoprotein receptor (LDLR). Using HepG2 human hepatoma cells, we found that BBR inhibits cholesterol and TG synthesis in a similar manner to the AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide 1-beta-ribofuranoside (AICAR). Significant increases in AMPK phosphorylation and AMPK activity were observed when the cells were incubated with BBR. Activation of AMPK was also demonstrated by measuring the phosphorylation of acetyl-CoA carboxylase, a substrate of AMPK, correlated with a subsequent increase in fatty acid oxidation. All of these effects were abolished by the mitogen-activated protein kinase kinase inhibitor PD98059. Treatment of hyperlipidemic hamsters with BBR decreased plasma LDL cholesterol and strongly reduced fat storage in the liver. These findings indicate that BBR, in addition to upregulating the LDLR, inhibits lipid synthesis in human hepatocytes through the activation of AMPK. These effects could account for the strong reduction of plasma TGs observed with this drug in clinical trials.

References

Nov 12, 1982·Biochimica Et Biophysica Acta·J F Glatz, J H Veerkamp
Oct 1, 1996·Arteriosclerosis, Thrombosis, and Vascular Biology·F Benoist, T Grand-Perret
Jun 1, 1997·European Journal of Biochemistry·D G Hardie, D Carling
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Dec 1, 2001·Nature Medicine·T Grand-PerretM Issandou
Jul 4, 2003·The New England Journal of Medicine·Elizabeth G Nabel
Aug 21, 2003·JAMA : the Journal of the American Medical Association·John G Canto, Ami E Iskandrian
Sep 23, 2003·Endocrinology·Neil B RudermanEdward W Kraegen
Nov 5, 2003·Expert Opinion on Pharmacotherapy·Harold Bays, Evan A Stein
Apr 3, 2004·Nature Reviews. Drug Discovery·Neil Ruderman, Marc Prentki
Nov 9, 2004·Atherosclerosis. Supplements·T R PedersenUNKNOWN Scandinavian Simvastatin Survival Study Group
Feb 8, 2005·Biochemical and Biophysical Research Communications·Kazuhiko NakamaruEiichi Araki
Apr 29, 2005·Current Topics in Medicinal Chemistry·Hubert Scharnagl, Winfried März

❮ Previous
Next ❯

Citations

Jun 20, 2008·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Zhiqiang GaoKaifu Wang
May 18, 2010·Chinese Journal of Integrative Medicine·Min WuLong-tao Liu
Feb 9, 2012·Chinese Journal of Integrative Medicine·Hui DongLi Zhao
Jan 12, 2013·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·Arrigo F G CiceroClaudio Borghi
Nov 29, 2013·Journal of Medicinal Food·Mun Ock KimHyun Sun Lee
Feb 28, 2009·Acta Physiologica·G ZhouB B Zhang
Nov 10, 2010·The American Journal of Chinese Medicine·Siming GuanXin Fang
Dec 12, 2012·The American Journal of Chinese Medicine·Rie OhnishiAkiko Kojima-Yuasa
Nov 1, 2007·American Journal of Physiology. Endocrinology and Metabolism·Jun YinJianping Ye
Nov 17, 2010·PloS One·Yingying HanMing-Hui Zou
Feb 20, 2014·Journal of Natural Medicines·Chin Piow WongHiroshi Morita
Jan 5, 2013·Biochimica Et Biophysica Acta·S E KorsseW van Veelen
Oct 19, 2010·Evidence-based Complementary and Alternative Medicine : ECAM·Qian ZhangHeng Wang
Jul 12, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Yang LiuGuang Ji
Sep 13, 2011·Mediterranean Journal of Nutrition and Metabolism·Bruno TrimarcoSalvatore Crispo
Jan 5, 2012·Critical Reviews in Clinical Laboratory Sciences·Fathimath FaizFrank M van Bockxmeer
Apr 14, 2015·Seminars in Cancer Biology·Stephanie C CaseyDean W Felsher
May 17, 2007·Expert Opinion on Therapeutic Targets·Keith Suckling
Aug 27, 2013·Expert Opinion on Biological Therapy·Giuseppe DerosaPamela Maffioli
Jul 12, 2012·Expert Opinion on Biological Therapy·Giuseppe DerosaArrigo F G Cicero
Dec 1, 2010·Expert Opinion on Drug Discovery·Yuan YangBin Hong
Sep 15, 2010·Expert Opinion on Investigational Drugs·Parameswara Rao VuddandaSanjay Singh
Nov 3, 2015·Biological & Pharmaceutical Bulletin·Atsuyoshi NishinaHirokazu Kimura
Jan 19, 2016·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Arrigo F G Cicero, Alessandro Colletti
Aug 28, 2012·Molecular and Cellular Endocrinology·Ming ZhangYanjun Liu
Nov 1, 2013·Science China. Life Sciences·Jing YaoJianDong Jiang

❮ Previous
Next ❯

Related Concepts

Related Feeds

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.